These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 7521563)

  • 1. [The clinical and prognostic value of inversion of the PSA/PAP ratio in prostatic cancer].
    Morote Robles J; Lorente JA; Reig C; López Pacios MA; de Torres JA; Soler Roselló A
    Actas Urol Esp; 1994 May; 18(5):559-61. PubMed ID: 7521563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.
    Moul JW; Connelly RR; Perahia B; McLeod DG
    J Urol; 1998 Mar; 159(3):935-40. PubMed ID: 9474187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
    Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
    Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
    Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
    J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay].
    Akino H; Tsuka H; Okada K; Tsuchiya Y; Matsubara M; Arimura K
    Hinyokika Kiyo; 1995 Jun; 41(6):439-45. PubMed ID: 7544063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
    Stege R; Grande M; Carlström K; Tribukait B; Pousette A
    Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acid phosphatase, alkaline phosphatase and prostate-specific antigen--usefulness in the diagnosis of metastatic disease and follow-up.
    Bauer HW
    Prog Clin Biol Res; 1988; 269():33-42. PubMed ID: 2455908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
    Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
    Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
    Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A
    Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma.
    Ghossein RA; Rosai J; Scher HI; Seiden M; Zhang ZF; Sun M; Chang G; Berlane K; Krithivas K; Kantoff PW
    Urology; 1997 Jul; 50(1):100-5. PubMed ID: 9218026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml.
    Wiebe E; Rodrigues G; Lock M; D'Souza D; Stitt L
    Can J Urol; 2008 Jun; 15(3):4078-83. PubMed ID: 18570713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy.
    Slovin SF; Wilton AS; Heller G; Scher HI
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8669-73. PubMed ID: 16361552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer.
    Wang TY; Kawaguchi TP
    Ann Clin Lab Sci; 1986; 16(6):461-6. PubMed ID: 3800301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of androgen independence in metastatic prostate cancer.
    Sim HG; Lau WK; Cheng CW
    BJU Int; 2004 Jun; 93(9):1221-4. PubMed ID: 15180610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.